NCT06929624

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.

Conditions

• Diffuse Large B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	SHR-A1912 Injection	SHR-A1912 injection.
DRUG	Rituximab Injection	Rituximab injection.
DRUG	Gemcitabine Hydrochloride for Injection	Gemcitabine hydrochloride for injection.
DRUG	Oxaliplatin Injection	Oxaliplatin injection.

Timeline

• Start date: 2025-04-24
• Primary completion: 2027-03-01
• Completion: 2028-01-01
• First posted: 2025-04-16
• Last updated: 2025-11-18

Locations

2 sites across 1 country: China